The implementation of Tolnagro Kft.'s project with identification number BAR-1.1.1-22-2022-00016 entitled "Technology development at Tolnagro Kft.'s Gumygyár Street site" has begun.

The implementation of Tolnagro Kft.'s project with identification number BAR-1.1.1-22-2022-00016 entitled "Technology development at Tolnagro Kft.'s Gumygyár Street site" has begun.

Tolnagro Állatgyógyászati Kft. was founded in Szekszárd in 1996. The Tolnagro group is a 100% Hungarian and family-owned group of companies with a history of 25 years, which is a key player in Hungarian agriculture and a market leader in the wholesale of veterinary products. With the experience gathered over the past 25 years, we strive for the highest possible standard and serve our nearly 22,000 partners from our selection of more than 18,000 products, both online and through our traditional (offline) platforms. The turnover of the 100% Hungarian-owned family business was HUF 25 billion in 2020.

The main activity of our company is the wholesale and retail trade of medicines and medical products, as well as the trade of food for farm animals and pets. However, in addition to the commercial activity, the production activity of the own product, with which the commercial units are supplied, is also getting stronger, so the production activity of the pharmaceutical product and the subject of development 2120'08 Medicinal product is also getting stronger.

The Company implements the following development out of HUF 80 685 298 awarded in the tender.

The key to the development and economic growth of the Tolnagro group is how independent we are from foreign suppliers and contract manufacturers. The solution is clearly if, based on the pedigrees owned by our company, we can produce our products in one place, with the best quality and the fastest time, with our own technological developments and with the specialists we have trained. The goal of the development is to create a modern veterinary pharmaceutical factory and laboratory in Budapest that meets the expectations of the 21st century. Thanks to the modern production technologies that will become available with the new plant, not only the quality of our products could be improved, but also our product range would be significantly expanded, as a result of which the range of products currently imported from the United Kingdom would become replaceable, thus eliminating the negative effects of foreign dependence and Brexit. As a result of our research and development activities, our existing portfolio can be supplemented with another 100-150 products thanks to the planned investment. However, the development is not only to reduce the import difficulties of the companies of the group of companies, but also to create production capacities that will replace the current dependence on the United Kingdom and the procurement difficulties due to Brexit with domestic production.

The detailed material and technical content of the development was designed in such a way that it fully meets the GMP pharmaceutical production conditions, and an automated and digitalized system to the greatest extent is implemented.

Technology development covers several areas, which include both production and additional areas related to production (wastewater treatment system). During the development, technological equipment and tools are purchased. It intends to implement the development in the tender by purchasing equipment used for the production of veterinary medicinal products and for the treatment of water produced during production. A colloid mill system and a purified water production system will be purchased to expand production capacities.

Actual completion of the project: 30.03.2024.